Home About us Reports Charts News Custom Company Scan  
Report Charts News
Title Content
Life Sciences
  Metals & Minerals
Public Sector
  Finance Service
  Real Estate
Technology And Media

Tel: 0086-10-82600828
Fax: 0086-10-82601570

 Techpool Bio-pharma Co. is to cooperate with Takeda after successful experience with Roche
CreateTime:2013-12-16 Editor:liaoyan
Text Size:       

The introduction of the exclusive distribution right of the third generation diphosphonate drug for the treatment of osseous metastasis - Ibandronic Acid Injection (brand name: Bondronat®) in mainland China from Roche Group has helped Techpool gain 1% of domestic market.

After the successful cooperation with national big pharma, Techpool has started to negotiate with Japanese pharmaceutical companies Takeda on the introduction of severe disease and cancer related medication.

Techpool is the global leader in urinary protein biopharmaceuticals which specializes in the sales, R&D and production of biopharmaceuticals in critical care. It is expected that Techpool shall have revenue between RMB 2billion to 4billion in 2016 and become the top 5 global bio-pharma companies.

Related Reports
China Animal Vaccine Industry Report, 2019-2025
China Blood Product Industry Report, 2020-2026
China Vacuum Blood Collection Device Industry Report, 2019-2025
China Human Vaccine Industry Report, 2019-2025
China Independent Clinical Laboratory Industry Report, 2019-2025
2005-2021 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1